Drug
Mavorixafor
Mavorixafor: highest development phase Phase 3, developed by X4 Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- X4 Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mavorixafor NCT06056297 | Phase 3 | Neutropenia |
Latest
No recent events.
Follow Mavorixafor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.